Abstract
BackgroundResearch indicates that aging and health are affected by hundreds of biochemical pathways. Our hypothesis is that a multipath intervention strategy directed at multiple aging pathways may promote overall health. The objective of the study was to test the effects of a multipath antiaging dietary supplement on healthy adults using known markers of health.MethodsThe design of the dietary supplement intervention clinical study was an open-label field study. Fifteen men and women aged 42 to 79 years took a 10 component dietary supplement SC100+ twice daily for 15 weeks. Markers of overall health and life expectancy were measured at baseline and after 15 weeks of treatment. The markers included blood pressure, heart rate, HDL and Total Cholesterol, Stress levels, Lung capacity, and HbA1c. Paired two-sided Student t-tests were performed to evaluate the significance of the differences between baseline and post treatment.ResultsMean laboratory measurements taken at baseline and after 15 weeks of SC100+ showed: 1) Systolic and diastolic blood pressure were both reduced (SBP -10.1 +/− 6.37 mmHg, p = 0.013 and DBP -4.6 +/− 4.17 mmHg, p = 0.048); 2) Stress as measured by heart rate variability was reduced (−25%, p = 0.017); 3) HDL cholesterol was increased (7.9 +/− 2.9 mg/dL, p = 0.005); and 4) Lung capacity was increased (+16.6%, p = 0.001). There were no significant changes in heart rate, total cholesterol, or HbA1c levels and no reported side effects.ConclusionsTargeting multiple aging pathways has the potential to significantly reduce blood pressure and stress, while significantly increasing HDL Cholesterol levels and lung capacity. Targeting multiple critical aging pathways with a single dietary supplement is a novel alternative strategy to promote overall health.Trial registrationThe open label pilot study was registered retrospectively on Feb. 8, 2017 (NCT03052491).
Highlights
Research indicates that aging and health are affected by hundreds of biochemical pathways
In developing SC100+, we started with the major active compounds found in the composite multipath supplement that increased mean and maximum lifespan in Drosophila [3] and added other nutraceutical compounds known to act on other critical age-related pathways
SC100+ was tested in an open label pilot study We have carried out an Institutional Review Board (IRB) approved clinical trial using 10 active component multipath formulation described above to treat human volunteers for a period of 15 week duration
Summary
Research indicates that aging and health are affected by hundreds of biochemical pathways. The fact that many genes have altered expression with age suggests the hypothesis that a multipath strategy to nudge the expression of many critical genes back toward. To test this composite multipath hypothesis in humans, we have completed a small open-label clinical trial that. In developing SC100+, we started with the major active compounds found in the composite multipath supplement that increased mean and maximum lifespan in Drosophila [3] and added other nutraceutical compounds known to act on other critical age-related pathways. The final 10 herbal extracts in SC100+ provide a diverse set of bioactive compounds, which appear to act on many of the critical health and longevity pathways
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
